| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TRVI | Common Stock | Options Exercise | $56.2K | +17.5K | +38.34% | $3.21 | 63.2K | 10 Mar 2025 | Direct | F1 |
| transaction | TRVI | Common Stock | Options Exercise | $250K | +63.8K | +101.05% | $3.91 | 127K | 10 Mar 2025 | Direct | F1 |
| transaction | TRVI | Common Stock | Options Exercise | $16K | +31.3K | +24.61% | $0.51 | 158K | 10 Mar 2025 | Direct | F1 |
| transaction | TRVI | Common Stock | Sale | -$518K | -77K | -48.65% | $6.73 | 81.3K | 10 Mar 2025 | Direct | F2, F3 |
| transaction | TRVI | Common Stock | Sale | -$31.1K | -4.35K | -5.35% | $7.15 | 76.9K | 10 Mar 2025 | Direct | F2, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TRVI | Performance Stock Option (right to buy) | Award | $0 | +38.4K | $0.00 | 38.4K | 10 Mar 2025 | Common Stock | 38.4K | $2.38 | Direct | F5 | |
| transaction | TRVI | Performance Stock Option (right to buy) | Options Exercise | $0 | -17.5K | -100% | $0.00 | 0 | 10 Mar 2025 | Common Stock | 17.5K | $3.21 | Direct | F6 |
| transaction | TRVI | Stock Option (right to buy) | Options Exercise | $0 | -63.8K | -85.08% | $0.00 | 11.2K | 10 Mar 2025 | Common Stock | 63.8K | $3.91 | Direct | F7 |
| transaction | TRVI | Stock Option (right to buy) | Options Exercise | $0 | -31.3K | -62.5% | $0.00 | 18.8K | 10 Mar 2025 | Common Stock | 31.3K | $0.51 | Direct | F8 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024. |
| F2 | This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| F5 | Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied. |
| F6 | Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. |
| F7 | This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024. |
| F8 | This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |